Rely-on-existing-data Approval

Rely-On-Existing-Data Approval is a regulatory pathway that authorizes new therapeutic uses of previously approved drugs by predominantly leveraging preexisting clinical, pharmacological, and safety data, rather than requiring de novo clinical trials, to demonstrate efficacy and safety for the repurposed indication.

0

Publications

0

Citations

0

Authors

0

Institutions

Authors

0

  1. NB
    Nicky Best

    Imperial College London, United Kingdom

    1 publications · 13 citations

    0

    h-index

  2. CS
    Cliff Shelton

    Wythenshawe Hospital, United Kingdom

    1 publications · 13 citations

    0

    h-index

  3. AF
    Andrew Fowler

    GlaxoSmithKline (United States), United States

    1 publications · 13 citations

    0

    h-index

  4. JH
    J. H. Crawford

    Langley Research Center, United States

    1 publications · 13 citations

    0

    h-index

  5. LZ
    Lu Zi

    Hebei Normal University, China

    1 publications · 13 citations

    0

    h-index

1–5 of 0

Institutions

0

  1. West Middlesex University Hospital

    London, United Kingdom

    1 publications

    13 citations

  2. GlaxoSmithKline (Germany)

    Hamburg, Germany

    1 publications

    13 citations

  3. Providence College

    Providence, United States

    1 publications

    13 citations

  4. GlaxoSmithKline (China)

    Beijing, China

    1 publications

    13 citations

1–4 of 0

Venues

  1. Therapeutic Innovation & Regulatory Science

    TIRS · 1 publications · 13 citations

1–1